RxDoctor Payments Data

Edward Ajayi, MD

Psychiatry · Smyrna, GANPI 1285649707

Payments from drug & device makers

$1,207in general payments, 2019–2025

Across 58 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$258
  • Teva Pharmaceuticals USA, Inc.$172
  • Johnson & Johnson$126
  • Avanir Pharmaceuticals, Inc.$125
  • Vanda Pharmaceuticals Inc.$112
  • Otsuka America Pharmaceutical, Inc.$88
  • plus $326 from 8 others

What the payments were for

  • Food & beverage$1,05687%
  • Education$15113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 65th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$57,625
Medicare patients
157
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate124$352,012
VraylarCariprazine Hcl174$261,095
Abilify MaintenaAripiprazole78$224,957
AustedoDeutetrabenazine47$186,571
FanaptIloperidone34$121,521
AristadaAripiprazole Lauroxil37$112,562
Invega TrinzaPaliperidone Palmitate11$96,177
Lurasidone Hcl103$38,750
VivitrolNaltrexone Microspheres22$35,278
Clozapine251$32,776
Divalproex Sodium ErDivalproex Sodium927$32,134
Aripiprazole431$31,102
TrintellixVortioxetine Hydrobromide29$18,739
Risperdal ConstaRisperidone Microspheres12$15,037
Fluoxetine Hcl610$11,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$126$463,225147 claims
AbbVieVraylar$258$261,095174 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$88$224,95778 claims
Teva Pharmaceuticals USA, Inc.Austedo$172$186,57147 claims
Alkermes, Inc.Aristada, Vivitrol$87$147,84059 claims
Vanda Pharmaceuticals Inc.Fanapt$112$121,52134 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$18,73929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →